Showing results (91-100 of 153) with videos related to

Sort By:
Pageof 16
The Korean Journal of Internal Medicine|January 25, 2024
Prognostic Significance Of Sequential 18f-fdg Pet/Ct During Frontline Treatment Of Peripheral T Cell LymphomasGa-Young Song, Sung-Hoon Jung, Seo-Yeon Ahn, et al.
Chonnam Medical Journal|April 28, 2015
Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to ClinicMy-Dung Hoang, Sung-Hoon Jung, Hyun-Ju Lee, et al.
Annals of Hematology|February 14, 2019
Different prognostic effects of core-binding factor positive AML with Korean AML registry dataHo-Jin Shin, Woo-Sung Min, Yoo Hong Min, et al.
Cancer Immunology, Immunotherapy : CII|November 17, 2022
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft modelJaya Lakshmi Thangaraj, Sung-Hoon Jung, Manh-Cuong Vo, et al.
Heliyon|March 25, 2024
Exploring cellular immunotherapy platforms in multiple myelomaManh-Cuong Vo, Sung-Hoon Jung, Van-Tan Nguyen, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 13, 2010
Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II studyDeok-Hwan Yang, Yeo-Kyeoung Kim, Sang-Kyun Sohn, et al.
Acta Haematologica|August 30, 2014
Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working PartyJae-Sook Ahn, Deok-Hwan Yang, Sung-Hoon Jung, et al.
Cellular & Molecular Immunology|May 13, 2021
Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse modelJaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung-Hoon Jung, et al.
Annals of Hematology|December 15, 2012
Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab eraDeok-Hwan Yang, Jae-Sook Ahn, Byung Hyun Byun, et al.
The Korean Journal of Internal Medicine|June 9, 2023
The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabineMihee Kim, TaeHyung Kim, Seo-Yeon Ahn, et al.
Pageof 16